PLoS ONE (Jan 2014)

Laser-supported CD133+ cell therapy in patients with ischemic cardiomyopathy: initial results from a prospective phase I multicenter trial.

  • Alexander Assmann,
  • Michael Heke,
  • Patric Kröpil,
  • Lena Ptok,
  • Dieter Hafner,
  • Christian Ohmann,
  • Andreas Martens,
  • Antje Karluβ,
  • Maximilian Y Emmert,
  • Ingo Kutschka,
  • Hans-Hinrich Sievers,
  • Hans-Michael Klein

DOI
https://doi.org/10.1371/journal.pone.0101449
Journal volume & issue
Vol. 9, no. 7
p. e101449

Abstract

Read online

This study evaluates the safety, principal feasibility and restoration potential of laser-supported CD133+ intramyocardial cell transplantation in patients with ischemic cardiomyopathy.Forty-two patients with severe ischemic cardiomyopathy (left ventricular ejection fraction (LVEF) >15% and 3 myocardial segments) determined in the preoperative MRI was inversely correlated with a LVEF increase after laser-supported cell therapy (p = 0.024).This multicenter trial demonstrates that laser-supported CD133+ cell transplantation is safe and feasible in patients with ischemic cardiomyopathy undergoing CABG, and in most cases, it appears to significantly improve the myocardial function. Importantly, our data show that the beneficial effect was significantly related to the extent of transmural delayed enhancement, suggesting that MRI-guided selection of patients is mandatory to ensure the effectiveness of the therapy.EudraCT 2005-004051-35) Controlled-Trials.com ISRCTN49998633.